Aardvark Therapeutics Inc (AARD) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Aardvark Therapeutics Inc   (NASDAQ: AARD)


Aardvark Therapeutics Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Aardvark Therapeutics Inc's ROI in the second quarter of 2026?
Aardvark Therapeutics Inc recorded a cumulative net loss of $-70 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -71.38%.

Within the Healthcare sector 346 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 3524 to 3794.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM -20.03 % 28.69 % 156.94 % - -
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 75 87 107 122 137
Return On Investment (TTM) -71.38 % -61.6 % -44.49 % -31.87 % -29.92 %
AARD's Overall Ranking # 3794 # 3524 # 3260 # 0 # 0
Seq. Investment Change TTM -13.69 % -12.37 % -15.43 % 25.01 % 38.9 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -70 -70 -58 -49 -37

AARD Company Profile >> Back to AARD Roi Comparisons >> See Annual AARD Return On Investment



Return On Investment AARD's Ranking
Within: No.
Industry # 142
Sector # 347
Overall # 3794

Return On Investment Statistics
High Average Low
-24.65 %
-50.58 %
-71.46 %
(Mar 31 2025)   (Jun 30 2026)



  News about Aardvark Therapeutics Inc Return on Investment ROI

Aardvark Therapeutics Pioneering Innovations in Obesity Management with ARD-201

November 4, 2025

In the ever-evolving landscape of obesity treatment, Aardvark Therapeutics has emerged as a beacon of innovation. Recent presentations at ObesityWeek 2025 underscored the company’s commitment to addressing one of the most pressing health issues of our time. Central to their focus is a promising candidate drug, ARD-201, which recently showcased exciting preclinical results that may redefine metabolic management for individuals battling obesity. The Challenge of Obesity: A Multifaceted ApproachObesity is not just a cosmetic issue; it is a complex metabolic disorder that requires a multi-pronged approach to treatment. Current interventions often fall short in achieving sustainable weight loss while preserving lean muscle mass, which is crucial for overall metabolic health. With global obesity rates soaring, there is an urgent need for innovative solutions that offer comprehensive benefits beyond mere weight loss.





Financial Statements
Aardvark Therapeutics Inc's II. Quarter Investments $ 75 Millions AARD's Balance sheet
Aardvark Therapeutics Inc's II. Quarter Income $ -14 Millions Quarterly AARD's Income Statement
AARD's Income by Division See AARD's Income by Division


AARD Annual Return On Investment (Dec 31 2025)
2025



Total Investments in Millions 107 0 0 0 0
Y / Y Investment Growth - - - - -
Net Income in Millions -58 0 0 0 0
Y / Y Net Income Growth - - - - -
Annual Return On Investment -54.01 % - - - -


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
AARD's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for AARD's Competitors
Subscribers only: Roi for Aardvark Therapeutics Inc's Suppliers
Subscribers only: Return On Investment for AARD's Customers

Other Ratios
AARD's Roa AARD's Inventory Turnover Ratio AARD's Growth Rates AARD's Dividend Statistics
AARD's Profitability Ratios AARD's Asset Turnover Ratio AARD's Dividend Growth
AARD's Roe AARD's Valuation Ratios AARD's Financial Strength Ratios AARD's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI

Date modified: 2026-09-04T23:59:15+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.